I’ll start right off with, I’m holding BCEL. Came in at 9, bought at 7.50, bought at 5, bought at upper 3’s and have a purchase order on for Monday. I’ve been buying CSP’s and selling CSP’s all the way down. Every DD I’ve read is positive. Every analyst has it as a buy. It lost in Q3, but a loss was predicted and it met the predictions. No surprises. Absolutely no comment from the company in months. All they have on their agenda is to speak at a few conferences. There have been some whispers of a buyout but the share price had to be driven down to make that happen. Any thoughts on what is going on and where this is headed?
After announcing results from their Phase 1 lead drug ATRC-101, the stock took a drastic tumble by the big institutions shorting it like they did with other companies like BBIG, XELA, AMC, SPRT, ANY, PROG, just to name a few.
The Institution Ownership is 91.30% which is very high, so there is something the institutions like about the company or they would have sold all their shares completely by now.
Since most institutions own the stock, that also tells me that there are less shares to short. Of lately the daily volume has been around 458,200 which is very small, could you imagine if the volume increased with the amount of shorted shares and with a float of only 22M, that would sky rocket the price in no time. This is also a long term stock so you can have it both ways.
Market cap: 225M.
Shorted: 22.73%
Short Borrow fee: 0.66%
Days to Cover: 4.80
Float: 22M
Average Volume: 1,081,864
Daily volume: 458,200
If you are looking to make high returns in a short space of time, then you will thank me for this one. I am not a financial advisor so everything here is just for info.
BCEL(Aterca) is a biopharmaceutical company that I have been talking about a lot lately and for good reasons only. BCEL(Aterca) discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Their latest completed Phase 1 drug trial was on their lead product ATRC-101.
Ever since the readout of their drug trial the stock had taken a real big tumble, but starting from next week this may all change. The reason for this is because Aterca will be presenting a upcoming virtual conference for investors starting from September 13 - 15 2021.
The virtual conference may contain some useful information for investors, stuff like the company's future plans, drug trial results in further detail and other major things that may interest them.
Check out the link below for more info:
https://finance.yahoo.com/news/atreca-present-upcoming-virtual-investor-203000768.html
The Institution Ownership for the company is 91.30% which is very high. When a stock has high institutional ownership, it is usually a good sign. If the institutions which include large investment banks, mutual funds and pension funds are the smart money in the market, having them invest in the company indicates the company is doing well or there is something they like about it.
But on top of that the company has also been shorted by 22.73%, days to cover ratio is 4.80% and the float is 22M. It is looking Bullish in the options chain and it is approaching the 50 day moving average. All these indications makes it a good sign that a short squeeze can occur.
Since most institutions own the stock, that also tells me that there are less shares to short. Of lately the daily volume has been around 458,200 which is very low, if the volume increased in a day with the amount of shorted shares and a float of only 22M, that would make the price skyrocket in no time.
Right now this stock is undervalued. Analysts at Wall Street Journal expect a target price up to $30 and class it as a buy at discount price. Info below:
https://www.wsj.com/market-data/quotes/BCEL/research-ratings
This sto
... keep reading on reddit ➡Hello fellow degens,
Tried of buying high selling low? how about some actual DD of something that is revolutionary and happening right under our noses. I hope you enjoy.
I wrote this all myself. I think this is extremely valuable and perhaps a once in a lifetime opp. I hope you enjoy and those of you who do make a bunch of money consider giving 10% away to people who are dying of cancer in hospice because by the time they do the trials itll be too late for many.
Table of contents
- What is Atreca and did it drop ~50 % in the recent months with a 30-50% short interest
- Are they trying to steal shares for cheap?
- Current state of affairs and CEO’s comments during Jefferies interview on June 2nd
- The History of departures of executives a few months before an acquisition in Biotech
- Suspicious departure of Chief Business Officer
- Suspicious departure of Chief Scientific Office
- Why is Atreca an immediate Acquisition Target
- Merck’s acquisition target - Part 1 - Merck’s likely angling for Atreca since 2016 and now they have the cash
- Merck’s acquisition target - Part 2 - President of Research, Dr Dean Li specific remarks
- Seagen acquisition target
- Significant derisking factors as an acquisition
- Closing Summary
- Further reading
- Powerpoint link to this presentation - https://drive.google.com/file/d/1p7m-9SCfeADi4YXHZE-4VUKh8GLCgHtb/view
Float 18.55m
Tutes 92.02%
Insiders 3.63%
Short interest 6/15 30%
Short Ratio 6/15 19.91
Total cash $211.67m
Cash per share $5.74
Book value per share $7.33
July anyday Data drop catalyst
- This presentation is not to fully vet the science behind Atreca’s technology and science. That would require a >100 page presentation in itself. I will be adding some further readings at the end of the presentation for company background
- However I will be introducing some broad concepts so you understand the critical events around data readout that are screaming towards an acquisition
- This data readout could happen any day in July as communicated by Atreca’s management for their lead program ATRC101
- This is not financial advice do your own DD
Who is Atreca
- Atreca was formed in 2010 by Stanford researchers. Their focus is to reproduce antibodies produced in responding cancer patients that bind preferentially to numerous tumor types.
- It’s done with differentiated and prop
$BCEL Atreca stock with a narrow range breakout watch above 6.48 , see https://stockconsultant.com/?BCEL
#stocks #wallstreet #money #finance #stockmarket
July has crushed biotech again so I see a lot of value.
I am a biotech investor who has studied a number of university drug development courses. I am not medically qualified. Please complete your own DD before investing in any company.
Atreca (BCEL)
Market Cap $260m
32 months cash runway (73% of market cap!)
Atreca is an interesting small cap with a novel approach using their platform to interrogate the active human immune response.
Data from Phase 1b of ATRC-101 for solid tumors is due before the end of the month. This precedes the enrolment for the 5th cohort (dosage of 30mg/kg.) There is no guarantee that the data will be presented before the end of the month.
They have designated further programmes and have scheduled an update at an R&D session before the end of the year on this and all their pipeline studies. Hopefully the patent for Atreca's Immune Repertoire Capture technology will be issued by then.
Visit wwwatreca.com to view their pipeline and patent information in full.
I see no reason for the data to fall short. The share price has bounced around a lot in the past couple of weeks. In the last session (Friday) I took the opportunity to greatly increase my holding at prices just above $7.00. I like this company long term but there could be an opportunity to cash in some quick profit.
Atreca, Inc. (BCEL)
Avg Vol (3 month) 1.03M
Avg Vol (10 day) 1.29M
Shares Outstanding 30.18M
Implied Shares Outstanding 36.89M
Float 18.55M
Held by Insiders 3.29% Held by Institutions 94.51%
Shares Short (Jul 15, 2021) 6.92M
Short Ratio (Jul 15, 2021) 4.85
Short % of Float (Jul 15, 2021) 30.90%
Short % of Shares Outstanding (Jul 15, 2021) 18.74%
Shares Short (prior month Jun 15, 2021) 46.53M
Recently presented initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types.
02:34 PM EDT, 07/29/2021 (MT Newswires) -- Atreca (BCEL) slumped Thursday after initial data from an open-label trial of its ATRC-101 antibody drug candidate for selected advanced solid tumors showed eight of the 20 evaluable participants experienced stable disease although the other 12 saw their disease continue to progress.
The stock sank 39% to a record low of $5.01 a share in afternoon trading.
ATRC-101 was generally well-tolerated, the company said, adding it was continuing with dose expansion of ATRC-101 as a monotherapy and in combination with Merck's (MRK) Keytruda. It also is expecting to begin enrolling patients during the final three months of 2021 for a combination study of ATRC-101 with pegylated liposomal doxorubicin.
The monotherapy study results are expected in about a year with data from the combination studies due by in 2022.
Stock took a dump on that data to $4.80 from $7.80 area
Company has plenty of cash on hand and little debt and is trading near cash bt below book value
Balance Sheet
Total Cash (mrq) $211.67M
Total Cash Per Share (mrq) $5.74
Total Debt (mrq) $41k
Total Debt/Equity (mrq) 0.02
Current Ratio (mrq) 11.98
Book Value Per Share (mrq) $6.00
This baby is primed for a short and gamma squeeze if those Sept/Aug $5 calls get loaded for August we can get the ball rolling for a gamma for sept easily
Got a nice gap to fill up to $7.75
https://preview.redd.it/b36y58emnig71.png?width=1320&format=png&auto=webp&s=7648713f7e4ce6d52531183adb472d484ac95889
After announcing results from their Phase 1 lead drug ATRC-101, the stock took a drastic tumble by the big institutions shorting it like they did with other companies like BBIG, XELA, AMC, SPRT, ANY, PROG, just to name a few.
The Institution Ownership is 91.30% which is very high for an ownership of a small cap company. So that alone tells you that the big boys do see something in the company or so many wouldn't be owning it.
That's a sign right there!
Since most institutions own the stock, that also tells you that there are less shares to short. Of lately the daily volume is only 458,200 which is very small, could you imagine if the volume increased with the amount of shorted shares shorted and with a float of only 22M, that would make the price rise high in a short space of time.
Market cap: 225M.
Shorted: 22.73%
Short Borrow fee: 0.66%
Days to Cover: 4.80
Float: 22M
Average Volume: 1,081,864
Daily volume: 458,200
What in the world just happened? Looks like less than 4k volume caused the price to plummet 30%. Who knows something we don't know about the results of the clinical trials?
I don't know shit about stocks but this looks ridiculous.
After announcing results from their Phase 1 lead drug ATRC-101, the stock took a drastic tumble by the big institutions shorting it like they did with other companies like BBIG, XELA, AMC, SPRT, ANY, PROG, just to name a few.
The Institution Ownership is 91.30% which is very high, so there is something the institutions like about the company or they would have sold all their shares completely by now.
Since most institutions own the stock, that also tells me that there are less shares to short. Of lately the daily volume has been around 458,200 which is very small, could you imagine if the volume increased with the amount of shorted shares and with a float of only 22M, that would sky rocket the price in no time. This is also a long term stock so you can have it both ways.
Market cap: 225M.
Shorted: 22.73%
Short Borrow fee: 0.66%
Days to Cover: 4.80
Float: 22M
Average Volume: 1,081,864
Daily volume: 458,200
You will likely never read anything like this. Not exaggerating. Read on.
This is a solid company that came out of stanford with biggest shareholders Bill gates foundation, baker brothers wellington management and they have been funding them for almost 10 years now.
THE DATA READOUT CAN HAPPEN ANYDAY NOW IN JULY- as communicated by atreca management. they have never announced any human data before and you will find no match to their stellar preclinical data
shorts are already covering. This short squeeze is different where organically this company is likely to 10x even without a reddit buy.
Even if you don't participate I would recommend you read this article it is extremely informative.
Table of contents
- What is Atreca and did it drop ~50 % in the recent months with a 30-50% short interest
- Are they trying to steal shares for cheap?
- Current state of affairs and CEO’s comments during Jefferies interview on June 2nd
- The History of departures of executives a few months before an acquisition in Biotech
- Suspicious departure of Chief Business Officer
- Suspicious departure of Chief Scientific Office
- Why is Atreca an immediate Acquisition Target
- Merck’s acquisition target - Part 1 - Merck’s likely angling for Atreca since 2016 and now they have the cash
- Merck’s acquisition target - Part 2 - President of Research, Dr Dean Li specific remarks
- Seagen acquisition target
- Significant derisking factors as an acquisition
- Closing Summary
- Further reading
- Powerpoint link to this presentation - https://drive.google.com/file/d/1p7m-9SCfeADi4YXHZE-4VUKh8GLCgHtb/view
- same post on another reddit thread - https://www.reddit.com/r/Stock_Picks/comments/oiashf/bcel_43_reasons_why_atreca_q3_2021_acquisition_is/
Float 18.55m
Tutes 92.02%
Insiders 3.63%
Short interest 6/15 30%
Short Ratio 6/15 19.91
Total cash $211.67m
Cash per share $5.74
Book value per share $7.33
July anyday Data drop catalyst
- This presentation is not to fully vet the science behind Atreca’s technology and science. That would require a >100 page presentation in itself. I will be adding some further readings at the end of the presentation for company background
- However I will be introducing some broad concepts so you understand th
